(Singapore – 10:05 a.m. SGT--September 11, 2023) – Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to ...
Dr. Eric Singhi sat down with CURE to break down the findings from the phase 3 FLAURA2 study, presented at the 2025 IASLC World Conference on Lung Cancer. Dr. Eric Singhi sat down with CURE to break ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback